Article

Acute Stroke Predicts Negative Outcome in COVID-19 Patients With Neuroimaging Findings

Patients with acute large ischemic and hemorrhage stroke had much higher mortality risk adjusted for age.

Rajan Jain, MD

Rajan Jain, MD

According to research published in the Journal of the Neurological Sciences, acute stroke is the most common neurimaging finding in patients with COVID-19, but capturing images can be complicated. Notably, half of hospitalized COVID-19 positive patients who have neuroimaging findings for acute stroke will die.

“Our data demonstrates, for the first time, that when neuroimaging shows acute large ischemic stroke or hemorrhagic stroke in admitted COVID-19 patients, it is one of the strongest prognostic markers of poor outcomes, even more than age and other previously reported co-morbidities, such as hypertension and obesity,” said lead study author Rajan Jain, M.D., neuroradiologist at NYU Langone Health. “COVID-19 patients who have a large ischemic or hemorrhagic stroke on imaging have a 50-percent mortality in the current study.”

To determine the incidence and kind of neuroimaging findings present in this patient group, Jain’s team conducted a retrospective study of 3,218 patients who had a confirmed COVID-19 diagnosis with the RT-PCR test who were admitted to three New York City hospitals between March 1 and April 13, 2020. Of the group, 454 patients (14.1 percent) underwent 716 neuroimaging studies — the number of studies accounted for 5.4 percent of 13,314 imaging exams of all types that were conducted on these patients during their entire hospitalization.

Head CT was the most common study (81.8 percent), with other studies including head and nect CT angiography, CT perfusion, brain MRI, MRA/MRV, and spine MRI. Clinical indications prompting most neuroimaging included altered mental status or delirium, stroke, and mechanical fall or trauma.

Among the overall patient group who underwent neuroimaging, 38 patients (8.4 percent) had acute neuroimaging findings. Based on study analysis, 14.1 percent of admitted COVID-19 patients underwent neuroimaging, accounting for 5.5 percent of total imaging studies. Of patients with positive neuroimaging studies, 92.5 percent had acute stroke, a finding that was present in 1.1 percent of COVID-19-postitive patients. For 63 percent of those patients positive for the virus with neuroimaging findings, signs of acute stroke were the initial COVID-19 manifestation.

Although these findings offer important information about neuroimaging and COVID-19, the investigators said, obtaining the images could be difficult.

“Neuroimaging studies have tended to constitute a larger percentage of overall diagnostic imaging use in hospital admitted patients,” they wrote. “However, COVID-19 being a pandemic associated primarily with pulmonary disease has led to the chest being the predominant [area] imaged.”

Overall, they said, there are three reasons why gathering neuroimages can be harder in this environment. First, they reported, the neurological complications, including delirium, encephalopathy, inflammatory neuropathy, and autonomic dysfunction, may not necessarily be associated with abnormalities seen on neuroimaging. Second, patient isolation combined with the need for strict precautions and stringent disinfection protocols may have limited the ability to conduct detailed neurological exams, as well as neuroimaging, particularly MRI. Third, critically ill patients are frequently intubated, making transport difficult and underdiagnosis possible. And, lastly, these patients are also often unconscious, making the identification of new neurological complications less likely.

“Our study also highlights the fact there is restricted use of neuroimaging in COVID-19 patients due to multiple logistical constraints, including the severity of their illness and the concern of spread of infection by imaging,” the team wrote.

Related Videos
2 experts in this video
2 experts in this video
2 experts in this video
Anna Pace, MD
Michael Levy, MD, PhD, is featured in this series.
Klaus Werner, MD & Alon Ironi
© 2024 MJH Life Sciences

All rights reserved.